Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181767 | 1.00 | MEN1 (0.60) | MEN1KMT2ALTA4HFKBP1ASMN1; SMN2 | |
| SCHEMBL19465330 | 0.96 | LTA4H (0.63) | MEN1KMT2ALTA4HFKBP1ASMN1; SMN2 | |
| SCHEMBL952722 | 0.96 | LTA4H (0.63) | MEN1KMT2ALTA4HFKBP1ASMN1; SMN2 | |
| SCHEMBL952721 | 0.96 | LTA4H (0.63) | MEN1KMT2ALTA4HFKBP1ASMN1; SMN2 | |
| SCHEMBL2768950 | 0.90 | FKBP1A (0.54) | MEN1KMT2ALTA4HFKBP1APOLB | |
| SCHEMBL1627052 | 0.86 | MEN1 (0.77) | MEN1KMT2AFKBP1ASMN1; SMN2POLB | |
| SCHEMBL13804314 | 0.84 | CNR2 (0.57) | MEN1KMT2ASMN1; SMN2POLBKDM4E | |
| SCHEMBL14598759 | 0.84 | CNR2 (0.57) | MEN1KMT2ASMN1; SMN2POLBKDM4E | |
| SCHEMBL14828717 | 0.84 | CNR2 (0.57) | MEN1KMT2ASMN1; SMN2POLBKDM4E | |
| SCHEMBL3713831 | 0.84 | SMN1; SMN2 (0.63) | MEN1KMT2ASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1294700-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | MEN1 629/4885KMT2A 2124/4885LTA4H 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.